Tianjin Lisheng Pharmaceutical's (SHE:002393) attributable profit rose to 370.7 million yuan in the first nine months of 2025 from 169.3 million yuan a year prior, a Friday Hong Kong bourse filing by parent Tianjin Development (HKG:0882) said.
Earnings per share came in at 1.44 yuan, up from 0.66 yuan in the year-ago period.
Total operating income during the nine-month period remained flat year-on-year at 1 billion yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.